WHO encouraging temperature-resistant vaccines; Seattle BioMed wins NIH AIDS grant;

> WHO wants to see temperature-resistant vaccines relabeled for use outside of the cold chain. Article

> Seattle BioMed has won a $9.8 million NIH grant for AIDS vaccine development. Release

> Allergy vaccine developer Circassia Pharmaceuticals has raised $333.5 million in its IPO. Piece

> An Indian rotavirus vaccine has been found safe and somewhat effective in a Phase III trial. News

> South Africa has begun providing free HPV vaccination for schoolgirls. Item

> Emergent BioSolutions is to develop vaccines using Valneva's EB66 cell line. Post

> CureVac has won a European innovation prize for work on temperature-resistant vaccines. Piece

Suggested Articles

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.